Aakash Desai

Aakash Desai Shared A Study Published In JTO on Datopotamab Deruxtecan In Patients With EGFR-mutated NSCLC

Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, posted on X:

“A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC – Journal of Thoracic Oncology.
Interesting analysis ahead of the U.S. FDA.
PDUFA date: July 12, 2025
Will we see another option in EGFRm NSCLC?” 

Datopotamab

Title: A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC

Journal: Journal of Thoracic Oncology

Authors: Myung-Ju Ahn, Aaron Lisberg, Yasushi Goto, Jacob Sands, Min Hee Hong, Luis Paz-Ares, Elvire Pons-Tostivint, Maurice Pérol, Enriqueta Felip, Shunichi Sugawara, Hidetoshi Hayashi, Byoung Chul Cho, George Blumenschein Jr., Elaine Shum, Jong-Seok Lee, Rebecca S. Heist, Robin Cornelissen, Wen-Cheng Chang, Dariusz Kowalski, Hong Zebger-Gong, Michael Chargualaf, Wen Gu, Lan Lan, Paul Howarth, Richard Joseph, Isamu Okamoto

Read the full article.

Datopotamab

More posts featuring Aakash Desai on OncoDaily.

Aakash Desai Aaron Lisberg Byoung Chul Cho cancer Dariusz Kowalski datopotamab deruxtecan EGFR-mutated NSCLC Elaine Shum Elvire Pons-Tostivint Enriqueta Felip FDA George Blumenschein Jr Hidetoshi Hayashi Hong Zebger-Gong Isamu Okamoto Jacob Sands Jong-Seok Lee Journal of Thoracic Oncology Lan Lan Luis Paz-Ares Maurice Pérol Michael Chargualaf Min Hee Hong Myung-Ju Ahn OncoDaily Oncology Paul Howarth PDUFA date Rebecca S. Heist Richard Joseph Robin Cornelissen Shunichi Sugawara U.S. FDA UAB O'Neal Comprehensive Cancer Center Wen Gu Wen-Cheng Chang Yasushi Goto